Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 116.77Cr 102.6Cr 96Cr 88Cr 164.53Cr 11TCr 168.59Cr 1.14TCr 444.14Cr 5.53TCr 438.4Cr 428.89Cr 19TCr P/E 2026 *
-7.74x
P/E 2027 * -7.01x
Enterprise Value 116.77Cr 102.6Cr 96Cr 88Cr 164.53Cr 11TCr 168.59Cr 1.14TCr 444.14Cr 5.53TCr 438.4Cr 428.89Cr 19TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 week+5.39%
Current month+4.94%
1 month+12.59%
3 months+23.01%
6 months+10.50%
Current year+43.33%
1 week 9.18
Extreme 9.182
10.9
1 month 8.64
Extreme 8.644
10.9
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
21.2
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%+5.39%+3.56%+34.56% 116.77Cr
-3.74%-6.32%+42.70%+63.37% 5.52TCr
-0.81%-0.33%+27.15%+81.12% 5.56TCr
-0.67%+0.12%-16.25%-15.34% 2.35TCr
-2.36%-7.10%-5.13%+351.72% 2.24TCr
-4.01%-2.68%+12.50%-12.70% 2.06TCr
-1.23%-3.15%+26.00%-33.84% 1.74TCr
-3.34%-6.96%+22.02%+515.48% 1.52TCr
+0.18%-0.66%+49.99%+180.47% 1.39TCr
-5.09%-13.14%+151.85%+272.20% 1.37TCr
Average -2.36%-1.55%+31.44%+143.70% 2.64TCr
Weighted average by Cap. -2.30%-0.46%+30.17%+120.51%

Financials

2026 *2027 *
Net sales - -
Net income -16Cr -14Cr -13Cr -12Cr -22Cr -1.5TCr -23Cr -151.98Cr -59Cr -740.63Cr -59Cr -57Cr -2.56TCr -19Cr -17Cr -16Cr -14Cr -27Cr -1.82TCr -27Cr -184.44Cr -72Cr -898.81Cr -71Cr -70Cr -3.11TCr
Net Debt - -
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
30/26/30 9.870 -0.20%
29/26/29 €9.890 -5.18%
28/26/28 €10.43 -2.75%
27/26/27 €10.73 +0.37%
24/26/24 €10.69 +11.53%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
11.28USD
Average target price
20.69USD
Spread / Average Target
+83.44%

Quarterly revenue - Rate of surprise